 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Novo Nordisk A/S (NVO) engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. 
It operates in two segments, Diabetes and Obesity care, and Biopharm.
The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.
The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc.
Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease.
On November 2nd, NVO reported 3rd Quarter September 2022 earnings of $0.86 per share on revenue of $6.2 billion. The consensus earnings estimate was $0.84 per share on revenue of $6.1 billion. Revenue grew 9.3% on a year-over-year basis. Since the report, shares have formed a bullish "cup and handle" and higher share prices are expected.
Entry Point: $135.00
Stop Loss: $129.00
Trading Range: $91.51 - $135.86
Target Price: $146.00
NVO closed at $143.
